Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79479.900.245%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Neumora Therapeutics Inc (NMRA) Stock Price, Quote, News & History

NMRANASDAQ
Trade with Public
Trade with Public
$1.31
-0.04-2.96%
At close: Sep 4, 5:00 PM EST
$1.31
N/A
After Hours: 7:01 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Neumora Therapeutics (NMRA) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$1.35
Close
$1.31
Volume / Avg.
549.21K / 1.84M
Day Range
$1.29 - $1.36
52 Wk Range
0.83 - 3.65
Market Cap
$246.14M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
36
Short Interest
7.27%
Days to Cover
13.4

Recent Neumora Therapeutics Inc News

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
Vandana Singh

Datadog, EHang Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures rise, Nasdaq 100 up 1%. Datadog (DDOG) downgraded, pre-market trading. Other decliners: CNCK, SLBT, MBGL, ZIM, GRVY, TALO, DPC, NMRA, FIP, HKD, EH, PSNY.
Avi Kapoor

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.
Avi Kapoor

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
Vandana Singh

Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June

US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial production up 0.1%. Housing market index declines to 35.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-180.52M
Investing Cash Flow (TTM)
94.03M
Financing Cash Flow (TTM)
78.80M
Free Cash Flow (TTM)
-180.52M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
-7.69M

Analyst Trends and Forecast

2
Mar
3
Jun
1
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$189.14M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
5.68
Earnings Yield % (TTM)
-91.45%
Earnings Yield % (FWD)
-47.21%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.24

Company Debt

Total Debt
$52.91M
LT Debt
$52.91M
LT Debt Issuance (TTM)
$38.76M
LT Debt Repayment (TTM)
-
Total Cash
$116.83M
Debt to Equity
1.20
Issuance of Debt (TTM)
$38.76M
Repayment of Debt (TTM)
-

Key Statistics

Open
$1.35
Close
$1.31
Volume / Avg.
549.21K / 1.84M
Day Range
$1.29 - $1.36
52 Wk Range
0.83 - 3.65
Market Cap
$246.14M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
36
Short Interest
7.27%
Days to Cover
13.4

About

Sector
Health Care
Industry
Pharmaceuticals
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pip...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Neumora Therapeutics (NMRA) stock?

A

You can purchase shares of Neumora Therapeutics (NASDAQ:NMRA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Neumora Therapeutics (NMRA) competitors?

Q

What is the forecast, or price target, for Neumora Therapeutics (NMRA) stock?

A

Neumora Therapeutics has a consensus price target of $5.88.

Q

What is the current price for Neumora Therapeutics (NMRA)?

A

The stock price for Neumora Therapeutics (NASDAQ: NMRA) is $1.31 last updated September 4, 2026 at 7:01 PM EDT.

Q

Does Neumora Therapeutics (NMRA) pay a dividend?

A

There are no upcoming dividends for Neumora Therapeutics.

Q

When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings?

A

Neumora Therapeutics does not have any upcoming earnings scheduled.

Q

Is Neumora Therapeutics (NMRA) going to split?

A

There is no upcoming split for Neumora Therapeutics.

Q

What sector and industry does Neumora Therapeutics (NMRA) operate in?

A

Neumora Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved